User login
RHODES, GREECE — Terbinafine is superior to placebo and comparable with other antifungal agents for the treatment of tinea pedis, Dr. Hans Christian Korting reported in a poster at the 15th Congress of European Academy of Dermatology and Venereology.
The finding is based on a meta-analysis of 19 randomized controlled trials including more than 2,300 patients. Various formulations of terbinafine, including cream, gel, and a new film-forming solution that requires only a single application, were compared with placebo or another antifungal.
The mycologic cure rate with terbi- nafine was significantly higher than with placebo (pooled relative risk 3.173), and tended to be higher, though not significantly, than with other antifungal agents (pooled relative risk 1.034), said Dr. Korting of Ludwig-Maximilians University in Munich, Germany.
There were no statistically significant differences in cure rates among the various terbinafine formulations. No conflicts of interest were disclosed.
RHODES, GREECE — Terbinafine is superior to placebo and comparable with other antifungal agents for the treatment of tinea pedis, Dr. Hans Christian Korting reported in a poster at the 15th Congress of European Academy of Dermatology and Venereology.
The finding is based on a meta-analysis of 19 randomized controlled trials including more than 2,300 patients. Various formulations of terbinafine, including cream, gel, and a new film-forming solution that requires only a single application, were compared with placebo or another antifungal.
The mycologic cure rate with terbi- nafine was significantly higher than with placebo (pooled relative risk 3.173), and tended to be higher, though not significantly, than with other antifungal agents (pooled relative risk 1.034), said Dr. Korting of Ludwig-Maximilians University in Munich, Germany.
There were no statistically significant differences in cure rates among the various terbinafine formulations. No conflicts of interest were disclosed.
RHODES, GREECE — Terbinafine is superior to placebo and comparable with other antifungal agents for the treatment of tinea pedis, Dr. Hans Christian Korting reported in a poster at the 15th Congress of European Academy of Dermatology and Venereology.
The finding is based on a meta-analysis of 19 randomized controlled trials including more than 2,300 patients. Various formulations of terbinafine, including cream, gel, and a new film-forming solution that requires only a single application, were compared with placebo or another antifungal.
The mycologic cure rate with terbi- nafine was significantly higher than with placebo (pooled relative risk 3.173), and tended to be higher, though not significantly, than with other antifungal agents (pooled relative risk 1.034), said Dr. Korting of Ludwig-Maximilians University in Munich, Germany.
There were no statistically significant differences in cure rates among the various terbinafine formulations. No conflicts of interest were disclosed.